Quest Diagnostics, a leading provider of diagnostic information services, has recently introduced a groundbreaking consumer-initiated test designed to help individuals evaluate their potential risk of developing Alzheimer’s disease. The innovative screening test, named AD-Detect, utilizes plasma obtained from a single blood draw to analyze levels of amyloid beta proteins. By detecting early signs associated with the risk of Alzheimer’s disease, the test aims to empower individuals in understanding their cognitive health.
At the core of Alzheimer’s disease lies amyloid, a sticky plaque that accumulates in the brain and is believed by some researchers to contribute to the progression of the illness. Notably, the U.S. Food and Drug Administration recently granted full approval to Leqembi, an anti-amyloid drug developed by Biogen and Eisai. Leqembi represents a new class of medications targeting amyloid and has showcased significant efficacy in slowing down cognitive decline among patients with early-stage Alzheimer’s.
Quest Diagnostics’ AD-Detect screening test employs the same advanced technology as its clinical AD-Detect Amyloid Beta 42/40 Ratio test, which was initially launched exclusively for physician ordering in early 2020. However, unlike its predecessor, this new test can be purchased directly by consumers without the need for an initial doctor’s appointment.
Stay updated on the latest medical advancements by engaging with Quest Diagnostics’ AD-Detect, your proactive step towards assessing Alzheimer’s risk.
